HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Arterial Occlusive Diseases (Arterial Occlusive Disease)

Subscribe to New Research on Arterial Occlusive Diseases

Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.

Also Known As:

Arterial Occlusive Disease; Arterial Obstructive Disease; Disease, Arterial Obstructive; Disease, Arterial Occlusive; Diseases, Arterial Obstructive; Diseases, Arterial Occlusive; Obstructive Disease, Arterial; Obstructive Diseases, Arterial; Occlusive Disease, Arterial; Occlusive Diseases, Arterial; Arterial Obstructive Diseases

Networked: 1243 relevant articles (69 outcomes, 183 trials/studies)

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 37259
- Vascular Diseases: 10289
  - Arterial Occlusive Diseases: 1243

Related Diseases

1.	Hypertension (High Blood Pressure)
2.	Stroke (Strokes)
3.	Ischemia
4.	Pain (Aches)
5.	Ulcer

Experts

1.	Zeller, Thomas: 8 articles (04/2014 - 10/2003)
2.	Linnemann, Birgit: 5 articles (04/2014 - 08/2006)
3.	Aschwanden, Markus: 5 articles (04/2014 - 01/2005)
4.	Bilecen, Deniz: 5 articles (04/2014 - 01/2005)
5.	Schulte, Anja-Carina: 5 articles (04/2014 - 01/2005)
6.	Schmidt, Andrej: 5 articles (02/2012 - 09/2005)
7.	Bosiers, Marc: 5 articles (02/2012 - 01/2008)
8.	Scheinert, Dierk: 5 articles (02/2012 - 06/2007)
9.	Minar, E: 5 articles (05/2006 - 12/2001)
10.	Sixt, Sebastian: 4 articles (04/2014 - 06/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Arterial Occlusive Diseases:

1.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 01/01/2000 - "Contrast-enhanced three-dimensional MR angiography is superior to DSA in revealing patent vessel segments of the foot in diabetic patients with severe arterial occlusive disease. " 05/01/1992 - "A double blind placebo controlled randomized study was used to assess the clinical variations caused by Sulodexide treatment (100 mg/die) vs placebo in 30 patients with a mean age of 50.3 years suffering from peripheral arterial obstructive disease of the lower limbs (II stage). " 01/01/2015 - "We prospectively compared the association between aortic wall stiffness, expressed by pulse wave velocity (PWV), sampled in the distal aorta, with the severity of peripheral arterial occlusive disease (PAOD) as compared to atherosclerotic markers sampled in remote vascular territories such as PWV in the proximal aorta and the normalized wall index (NWI), representing the vessel wall thickness, of the left common carotid artery. " 03/01/2014 - "Specific subsets of CLI patients have been identified to clearly benefit from open surgical revascularization based on presenting signs (extensive tissue loss), multi-level, long-segment arterial occlusive disease, healthy saphenous conduit, and nondiseased tibial artery target vessel with continuous patency to the pedal arch. " 03/01/2009 - "Given the high prevalence of arterial obstructive disease, a therapeutic compound stimulating collateral vessel growth could have a major impact on morbidity and mortality world wide. "
2.	Alprostadil (Muse)FDA LinkGeneric 01/01/1989 - "The study also demonstrated that PGE1 is more effective in the treatment of severe arterial occlusive disease than PX. " 10/01/1998 - "The results indicated that iontophoretically applied PGE1 was effective in improving the impaired microcirculation due to peripheral arterial occlusive disease. " 08/01/2004 - "Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV." 02/01/2003 - "In this study, we measured serum levels of MCP-1 in patients with peripheral arterial obstructive disease (PAOD) and investigated whether intravenous prostaglandin E1 (PGE1) treatment, which produces clinical benefits in PAOD, might decrease such levels. " 03/01/1999 - "In this study the action of an antiaggregatory prostaglandin, PGE1, was studied in a group of patients with peripheral arterial occlusive disease (PAOD). "
3.	cilostazol (Pletal)FDA LinkGeneric 05/01/2008 - "Cilostazol is a phosphodiesterase type 3 (PDE3) inhibitor that is effective in the treatment of symptoms of peripheral arterial occlusive disease. " 01/01/1985 - "Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) was evaluated experimentally to be effective in increasing blood flow in arterial occlusive disease. " 03/15/2001 - "Cilostazol, which increases intracellular cAMP in platelets, may be useful in the treatment of arterial occlusive diseases." 05/01/2008 - "The Cilostazol: A Study in Long-Term Effects (CASTLE) trial was a prospective randomized double-blinded trial to establish the safety of this PDE3 inhibitor use in 1435 patients with mild to moderate peripheral arterial occlusive disease. " 01/01/1997 - "This study demonstrates that cilostazol is an effective inhibitor of SIPA, which may be important for the prevention and the treatment of arterial occlusive diseases."
4.	reteplase FDA Link 03/01/2004 - "The safety and efficacy of increasing doses of intraarterial reteplase monotherapy and reteplase/abciximab combination therapy were examined in patients with acute peripheral arterial occlusive disease (PAOD). " 03/01/2004 - "Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial." 01/01/2002 - "Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study." 03/01/2000 - "Reteplase shows promise as an alternative to urokinase in the treatment of lower extremity ischemia due to arterial occlusive disease." 02/01/2004 - "Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion."
5.	abciximab (ReoPro)FDA Link 03/01/2004 - "The safety and efficacy of increasing doses of intraarterial reteplase monotherapy and reteplase/abciximab combination therapy were examined in patients with acute peripheral arterial occlusive disease (PAOD). " 03/01/2004 - "Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial." 01/01/2002 - "Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study." 03/01/2003 - "Both abciximab and tirofiban can be used successfully in patients with peripheral arterial occlusive disease and arterial thrombosis." 03/01/2003 - "Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis."
6.	Pain-FreeIBA 02/01/2004 - "The purpose of this study was to evaluate the efficacy of a pain-free treadmill walking program in intellectually disabled (ID) adults with arterial occlusive disease. " 01/01/2009 - "Does controlled vascular training influence plasmaviscosity and the pain free walking distance in patients with peripheral arterial occlusive disease (paod) Fontaine stage II?37 patients, 24 men and 13 women with a mean age of 64.5 years SD 8.5 took part in ambulant vascular training over a period of 12 months.Before" 01/01/2009 - "Influence of controlled vascular training on the pain free walking distance and plasmaviscosity in patients suffering from peripheral arterial occlusive disease." 06/15/1999 - "In 49 patients (33 men, 16 women, age 34 to 84 years) with Fontaine Stage II peripheral arterial occlusive disease the pain-free and absolute walking distance on the treadmill were measured under standardized conditions, as also the walking distance on the level at freely selected speed. " 01/01/1991 - "The method of nuclear magnetic resonance (NMR) spectroscopy compared to the parameters absolute-, pain-free walking distance and ankle/arm coefficient in Doppler pressure was used for observation of patients with peripheral arterial occlusive disease stage IIb according to Fontaine. "
7.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/01/2015 - "The key search terms ("aspirin," "PAD," "peripheral arterial occlusive diseases," and "claudication") produced 9 high-quality randomized controlled trials (RCTs) of aspirin versus placebo/control. " 11/01/2012 - "For peripheral arterial occlusive disease, a beneficial effect of aspirin is questioned by recent studies in contrast to the recommendations given in international guidelines. " 10/01/2009 - "Ninety-eight patients with stable peripheral arterial occlusive disease (PAOD) treated with 100 mg/d aspirin were followed over a median timeframe of 17 months. " 10/01/2009 - "Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up." 11/01/1996 - "In summary, aspirin is indicated in almost all patients with peripheral arterial occlusive disease, at least for preventing acute coronary or cerebrovascular events. "
8.	Nafronyl (Naftidrofuryl)IBA 03/01/1988 - "In a randomized, double-blind, placebo-controlled study in patients with peripheral arterial occlusive disease stage IIb of Fontaine's classification, the efficacy of naftidrofuryl, a vasoactive substance, was investigated. " 05/11/1984 - "The efficacy of naftidrofuryl ( Dusodril ) for treatment of stage II arterial occlusive disease was evaluated in a controlled multi-centre study in a total of 104 out-patients with angiographically documented localization of occlusion. " 01/01/1988 - "[Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease]." 01/01/1988 - "[Effect of intravenous naftidrofuryl on the microcirculation of patients in stages III and IV of arterial occlusive disease]." 01/01/1988 - "[Capillary microscopic effect of naftidrofuryl in peripheral arterial occlusive disease]."
9.	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/01/1989 - "Preliminary results of the use of prostacyclin in 6 patients with peripheral arterial occlusive disease (IV stage) are presented. " 01/01/1987 - "Prostacyclin in peripheral arterial occlusive disease (PAOD): clinical and hemodynamic findings in patients with PAOD stage III and IV." 08/01/1986 - "The efficacy of prostacyclin (PGI2) treatment was assessed in 26 patients with surgically unreconstructible atherosclerotic arterial occlusive disease of the lower extremity manifested by nonhealing ulcers and rest pain. " 08/01/1986 - "Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease." 01/01/1990 - "Iloprost is a potent, chemically stable prostacyclin-mimetic for which therapeutic efficacy has been proven in patients with peripheral arterial occlusive disease (PAOD) and in those suffering from Raynaud's phenomenon. "
10.	Glycoproteins (Glycoprotein)IBA 08/01/2004 - "This article will review the non-cardiac applications of glycoprotein IIb/IIIa inhibitors in the setting of acute ischemic stroke, carotid and vertebral angioplasty and stenting, acute critical limb ischemia, and percutaneous interventions in peripheral arterial occlusive disease." 03/01/2002 - "The purpose of this study was to evaluate the efficacy of eptifibatide, an inhibitor of the glycoprotein (GP) IIb/IIIa platelet receptor, in the thrombolytic treatment of patients with acute peripheral arterial occlusive disease. " 01/01/2013 - "Premature peripheral arterial occlusive disease was characterized by the presence of a family history of peripheral arterial and carotid artery diseases (OR 2.3 and 5.8 respectively, 95% CI), high lipoprotein (a) levels above 300 mg/L (OR 2.3, 95% CI), the presence of the factor V Leiden (OR 5.1, 95% CI) and the glycoprotein Ia(807T,837T,873A) allele (OR 2.3, 95% CI). " 02/01/2004 - "This study was designed to compare the ability of reteplase (a fibrinolytic agent) alone or in combination with abciximab (a monoclonal antibody antagonist of platelet glycoprotein IIb/IIIa) to achieve and sustain vessel patency in an acute model of peripheral arterial occlusive disease in cynomolgus monkeys. " 01/01/2002 - "To report the efficacy of catheter-directed thrombolysis with a combination of a thrombolytic agent (reteplase) and a glycoprotein (GP) IIb/IIIa platelet receptor antagonist (abciximab) in peripheral arterial occlusive disease. "

Therapies and Procedures

1.	Angioplasty (Angioplasty, Transluminal) 03/01/2010 - "The purpose of this study was to evaluate the efficacy of combined ipsilateral percutaneous iliac angioplasty and open infrainguinal surgical techniques for the treatment of patients with multilevel arterial occlusive disease. " 02/01/2010 - "To evaluate safety and efficacy of cryoplasty versus conventional angioplasty for focal popliteal arterial occlusive disease. " 09/01/1984 - "Efficacy of percutaneous angioplasty in lower extremity arterial occlusive disease." 06/05/2012 - "Eligible studies concerning treatment by subintimal angioplasty in patients with arterial occlusive disease of lower extremity were identified from electronic database, cross-reference search and relative articles. " 07/01/2008 - "The objective of this study was to summarize outcomes of subintimal angioplasty (SA) for peripheral arterial occlusive disease. "
2.	Stents 06/01/2013 - "This study aimed to determine if the different stent types used in the treatment of infrapopliteal arterial occlusive disease provide any significant advantage over one another at 6 and 12-month follow-up. " 12/01/2011 - "This trial was conducted to determine if covered stents offer a patency advantage over bare-metal stents in the treatment of aortoiliac arterial occlusive disease. " 08/01/2015 - "Patients eligible for inclusion were individuals suffering from symptomatic popliteal arterial occlusive disease (Rutherford-Becker stage 3-6; P1-P3 segments) and treated with placement of the TIGRIS stent(s). " 02/01/2014 - "To observe the intervention effect of Leihong Granule (LG) in in-stent restenosis (ISR) after endovascular therapy for lower extremity arterial occlusive diseases (LEAOD). " 02/01/2014 - "[Leihong granule intervened in-stent restenosis after endovascular therapy for lower extremity arterial occlusive diseases: a clinical observation]."
3.	Balloon Angioplasty 07/01/1999 - "And balloon angioplasty (PTA) is still accepted as the gold standard for chronic arterial occlusive disease. " 10/01/2008 - "The aim of this study was to evaluate the quality of life (QoL) and the effect of arterial balloon angioplasty (ABA) on QoL of patients with peripheral arterial occlusive disease (PAOD). " 12/01/2014 - "From April 2007 to November 2011, 48 limbs in 38 patients underwent endovascular stenting or balloon angioplasty to treat femoropopliteal arterial occlusive disease. " 02/01/2014 - "There have been rapid technological developments aimed at improving short- and long-term results of percutaneous transluminal balloon angioplasty (PTA) in peripheral arterial occlusive disease (PAD). " 09/01/2007 - "Commentary on "New techniques and developments of stenting for infrainguinal arterial occlusive disease: are the results any better than balloon angioplasty alone?"."
4.	Transplants (Transplant) 12/01/2014 - "We previously showed that duplex ultrasound (DU) imaging is beneficial in the diagnosis of failing vein and prosthetic grafts performed for arterial occlusive disease. " 08/01/1996 - "In this study, the efficacy of composite sequential bypass is compared to that of standard in situ bypass, and to alternate prosthetic graft systems which have been used for the treatment of multilevel infrainguinal arterial occlusive disease in the absence of suitable autogenous vein. " 02/01/2013 - "This study reports the authors' long-term results on the use of precuffed ePTFE grafts for infrainguinal bypasses in patients with arterial occlusive disease and compares these with results of reversed great saphenous vein grafts (rSVG). " 08/01/2011 - "The objective of this study was to describe the rate and predictors of SSI after surgery for arterial occlusive disease using national data, and to identify any association between SSI and length of hospital stay, reoperation, graft loss, and mortality. " 04/01/1996 - "To study the outcome of treating critical limb ischaemia due to concurrent, unilateral iliac and femoral arterial occlusive disease by the placement of a crossover femoropopliteal bypass graft. "
5.	Catheters 01/01/1993 - "Probably, also long-term results after catheter-based therapy of peripheral arterial occlusive disease may be improved by these new technologies." 10/01/1997 - "An invasive diagnostic procedure as angiography which involves direct arterial injection of contrast through suitable catheters, is still considered the gold standard in the evaluation of diabetic patients with peripheral arterial occlusive disease. " 01/01/2001 - "Contrast-enhanced moving-table MR angiography may be an effective alternative to catheter arteriography in endovascular and surgical treatment planning in selected patients with peripheral arterial occlusive disease, but larger studies are necessary to confirm this." 03/01/2010 - "CTA has displaced conventional catheter arteriography in a large range of applications and is predominantly used in the evaluation of atherosclerotic peripheral arterial occlusive disease in symptomatic patients who are candidates for intervention. " 03/01/2005 - "Dr. Dotter said, "The angiographer who enters into the treatment of arterial obstructive disease can now play a key role, if he is prepared and willing to serve as a true clinician, not just as a skilled catheter mechanic. "